CJC-1295 vs Hexarelin
Comprehensive side-by-side comparison of mechanisms, dosing, side effects, and research
Also: CJC-1295 DAC, CJC-1295 no DAC
A synthetic analog of growth hormone-releasing hormone (GHRH) that stimulates GH release from the pituitary. Often combined with a GHRP like Ipamorelin for synergistic effects.
Also: Examorelin, HEX
A synthetic hexapeptide GH secretagogue with the strongest GH-releasing effect among GHRPs. Also has notable cardioprotective properties independent of GH release.
Key Comparison Insights
- Both peptides belong to the Growth Hormone category, suggesting similar primary applications.
Detailed Comparison
| Attribute | CJC-1295 | Hexarelin |
|---|---|---|
| Category | Growth Hormone | Growth Hormone |
| FDA Status | Not FDA Approved | Not FDA Approved |
| Clinical Status | Pre I II III IV FDA | Pre I II III IV FDA |
| Mechanism of Action | CJC-1295 binds to GHRH receptors on the pituitary, stimulating GH synthesis and release. The DAC (Drug Affinity Complex) version binds to albumin, extending half-life to 6-8 days. Without DAC (Mod GRF 1-29), half-life is about 30 minutes. | Hexarelin activates ghrelin receptors (GHSR-1a) causing potent GH release. Uniquely, it also binds to CD36 receptors in cardiac tissue, providing cardioprotective effects independent of GH. Causes significant cortisol and prolactin elevation. |
| Common Dosing | 100 mcg daily (no DAC) or 2 mg weekly (with DAC) Daily (no DAC) or 1-2x weekly (with DAC) | 100-200 mcg 2-3x daily 2-3x daily |
| Administration | Subcutaneous injection | Subcutaneous injection |
| Typical Duration | 8-12 weeks | 4-8 weeks (desensitization occurs) |
| Best Time to Take | Before bed | Morning and before bed (fasted) |
Possible Side Effects May vary by individual |
|
|
| Research Summary | Phase II trial in HIV lipodystrophy patients was discontinued after a patient death (MI, deemed unrelated but trial ended as precaution). Earlier studies show sustained 2-10 fold increase in GH and IGF-1 levels with good tolerability at doses up to 60 mcg/kg. | Studies show the highest GH release among GHRPs but with desensitization over time. Cardiac research demonstrates protection against ischemia and improved heart function. Used in GH deficiency diagnosis due to reliable GH stimulation. |
Frequently Asked Questions: CJC-1295 vs Hexarelin
What is the difference between CJC-1295 and Hexarelin?
CJC-1295 is a growth hormone peptide that a synthetic analog of growth hormone-releasing hormone (ghrh) that stimulates gh release from the pituitary. often combined with a ghrp like ipamorelin for synergistic effects. Hexarelin is a growth hormone peptide that a synthetic hexapeptide gh secretagogue with the strongest gh-releasing effect among ghrps. also has notable cardioprotective properties independent of gh release. The main differences lie in their mechanisms of action and clinical applications.
Which is better, CJC-1295 or Hexarelin?
Neither is universally "better" - the choice depends on your specific goals. CJC-1295 is typically used for growth hormone purposes, while Hexarelin is used for growth hormone. Always consult with a healthcare provider to determine which may be appropriate for your situation.
Can CJC-1295 and Hexarelin be used together?
Some peptide protocols combine multiple compounds for synergistic effects. However, using CJC-1295 and Hexarelin together should only be considered under medical supervision, as both compounds have their own side effect profiles and potential interactions. Research on their combined use may be limited.
Related Comparisons
View Full Peptide Profiles
Educational Information Only
This comparison of CJC-1295 and Hexarelin is for educational purposes only. Neither this comparison nor any information on this site constitutes medical advice. Always consult with qualified healthcare providers before making decisions about peptides or other substances.